• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Metavention raises $65m to tackle diabetes with metabolic neuromodulation therapy

January 9, 2018 By Sarah Faulkner

diabetesMetavention said today that it closed a $65 million Series C round with funding from New Enterprise Associates, Sanderling Ventures and others.

The medical device maker plans to use the funds to optimize its transcatheter-based metabolic neuromodulation therapy for people with Type II diabetes and prepare it for a Phase II trial in the U.S.

Abnormally high blood glucose levels in people with diabetes have been associated with an overactive sympathetic nervous system, according to Metavention. The Minneapolis-based company noted that modulating SNS activity can reduce glucose levels.

In connection with the funding round, Metavention announced that it has named Todd Berg as its chief executive officer. Berg was formerly CEO of Torax Medical, which was bought by Johnson & Johnson‘s (NYSE:JNJ) Ethicon division last year.

“The Metavention mission to provide improved control of elevated glucose, in a single minimally invasive procedure, is very exciting. The approach represents a new frontier in medicine in which Metavention is uniquely positioned to provide the enabling technology and supporting science. I am honored to be joining the accomplished Metavention team at this pivotal stage,” Berg said in prepared remarks.

“This financing by a leading investor syndicate and our recruitment of a highly experienced, successful CEO further validates the transformative potential of MNT as the first procedure targeting one of the underlying causes of Type II diabetes,” founder, president & CMO Dr. Bobak Azamian added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Featured, Funding Roundup, Personnel Tagged With: johnsonandjohnson, metavention

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS